|
Post by silentbob on Apr 2, 2014 14:56:46 GMT -5
blogs.barrons.com/stockstowatchtoday/2014/04/02/mannkind-afrezza-recommendation-unexpected-success-not-guaranteed/So the bearish JPMorgan’s Cory Kasimov had this to say: "To put the potential commercial opportunity into perspective, Novolog generated $3B in sales last year and Humalog sold $2.6B. If Afrezza is deemed not as effective and has sub-optimal labeling, those numbers may potentially represent ceilings for this product." Oh, darn. It looks like we won't be having over $5.6 billion in revenues before we can do some more trials to improve the label. Oh well in that case we should all best sell our shares asap...
|
|
|
Post by mnkdd on Apr 2, 2014 15:42:20 GMT -5
I love how these analysts always fail the mention the most obvious: NO NEEDLES. Do they not realize that we live in America? Home of the drive-thru, remote control, microwave popcorn, etc etc etc.
|
|
|
Post by 4allthemarbles on Apr 2, 2014 22:24:42 GMT -5
After the second time around, a lot of analysts stated they thought Afrezza would ultimately be approved. Sometimes you have to wonder why all the AFs of the world get so much more attention then the ones with integrity.
|
|